Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01159821 · ClinicalTrials.gov registry record · Phase 1
A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers
A Phase 1 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01159821 is a Phase 1 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 14 participants.
The verdict
NCT01159821, a Phase 1 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the concentration of 31001074 in blood samples from healthy volunteers who have been administered 31001074 and paroxetine.
Interventions
- DRUG 31001074/paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-08 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01159821
The ClinicalTrials.gov registry entry for NCT01159821 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 31001074/paroxetine is the first listed.
NCT01159821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01159821 about?
NCT01159821 is a clinical study titled "A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers". The purpose of this study is to determine the concentration of 31001074 in blood samples from healthy volunteers who have been administered 31001074 and paroxetine.
What is the current status of trial NCT01159821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-08. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01159821?
The interventions under investigation include: 31001074/paroxetine (DRUG).
Who is sponsoring clinical trial NCT01159821?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.